{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T01:15:00Z","timestamp":1773710100586,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T00:00:00Z","timestamp":1672963200000},"content-version":"am","delay-in-days":339,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015615","name":"NIDA CTN","doi-asserted-by":"publisher","award":["UG1DA040316"],"award-info":[{"award-number":["UG1DA040316"]}],"id":[{"id":"10.13039\/100015615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.jsat.2021.108590","type":"journal-article","created":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T11:26:05Z","timestamp":1628249165000},"page":"108590","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Did drug use increase following COVID-19 relaxation of methadone take-out regulations? 2020 was a complicated year"],"prefix":"10.1016","volume":"133","author":[{"given":"Gavin","family":"Bart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solvejg","family":"Wastvedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James S.","family":"Hodges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsat.2021.108590_bb0005","series-title":"Provisional drug overdose death counts","author":"Ahmad","year":"2021"},{"issue":"1","key":"10.1016\/j.jsat.2021.108590_bb0010","doi-asserted-by":"crossref","first-page":"48","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting linear mixed-effects models using lme4","volume":"67","author":"Bates","year":"2015","journal-title":"Journal of Statistical Software"},{"issue":"12","key":"10.1016\/j.jsat.2021.108590_bb0015","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.3109\/10826080902962011","article-title":"Lessons learned from the deadly sisters: Drug and alcohol treatment disruption, and consequences from hurricanes Katrina and Rita","volume":"44","author":"Carlisle Maxwell","year":"2009","journal-title":"Substance Use & Misuse"},{"issue":"1","key":"10.1016\/j.jsat.2021.108590_bb0020","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/j.sapharm.2020.06.003","article-title":"Impact of COVID-19 related policy changes on filling of opioid and benzodiazepine medications","volume":"17","author":"Downs","year":"2021","journal-title":"Research in Social & Administrative Pharmacy"},{"issue":"1","key":"10.1016\/j.jsat.2021.108590_bb0025","first-page":"9","article-title":"\"Big Events\" and networks","volume":"27","author":"Friedman","year":"2006","journal-title":"Connections (Toronto, Ont.)"},{"issue":"3","key":"10.1016\/j.jsat.2021.108590_bb0030","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.drugpo.2008.10.006","article-title":"Theorizing \"Big Events\" as a potential risk environment for drug use, drug-related harm and HIV epidemic outbreaks","volume":"20","author":"Friedman","year":"2009","journal-title":"The International Journal on Drug Policy"},{"key":"10.1016\/j.jsat.2021.108590_bb0035","first-page":"108223","article-title":"Re-thinking patient stability for methadone in opioid treatment programs during a global pandemic: Provider perspectives","author":"Hatch-Maillette","year":"2020","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2021.108590_bb0040","first-page":"108222","article-title":"Unprecedented need and recommendations for harnessing data to guide future policy and practice for opioid use disorder treatment following COVID-19","author":"Livingston","year":"2020","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"5","key":"10.1016\/j.jsat.2021.108590_bb0045","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s11524-014-9904-5","article-title":"Effects of regulation on methadone and buprenorphine provision in the wake of hurricane Sandy","volume":"91","author":"McClure","year":"2014","journal-title":"Journal of Urban Health: Bulletin of the New York Academy of Medicine"},{"issue":"24","key":"10.1016\/j.jsat.2021.108590_bb0050","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1001\/jama.2020.21231","article-title":"Psychological distress and COVID-19\u2013Related stressors reported in a longitudinal cohort of US adults in April and July 2020","volume":"324","author":"McGinty","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jsat.2021.108590_bb0055","series-title":"42 CFR Part 8","year":"2001"},{"key":"10.1016\/j.jsat.2021.108590_bb0060","doi-asserted-by":"crossref","first-page":"103088","DOI":"10.1016\/j.drugpo.2020.103088","article-title":"Evidence of increased fentanyl use during the COVID-19 pandemic among opioid agonist treatment patients in Ontario, Canada","volume":"90","author":"Morin","year":"2021","journal-title":"The International Journal on Drug Policy"},{"issue":"S1","key":"10.1016\/j.jsat.2021.108590_bb0065","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1089\/pop.2020.0230","article-title":"The opioid epidemic within the COVID-19 pandemic: Drug testing in 2020","volume":"24","author":"Niles","year":"2021","journal-title":"Population Health Management"},{"issue":"7","key":"10.1016\/j.jsat.2021.108590_bb0070","doi-asserted-by":"crossref","first-page":"878","DOI":"10.3109\/10826084.2015.978675","article-title":"Immediate impact of hurricane Sandy on people who inject drugs in New York City","volume":"50","author":"Pouget","year":"2015","journal-title":"Substance Use & Misuse"},{"issue":"2","key":"10.1016\/j.jsat.2021.108590_bb0080","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1037\/1064-1297.6.2.162","article-title":"Medication take-home doses and contingency management","volume":"6","author":"Schmitz","year":"1998","journal-title":"Experimental and Clinical Psychopharmacology"},{"key":"10.1016\/j.jsat.2021.108590_bb0085","series-title":"ederal guidelines for opioid treatment programs","author":"Substance Abuse and Mental Health Services Administration","year":"2015"},{"key":"10.1016\/j.jsat.2021.108590_bb0090","author":"Substance Abuse and Mental Health Services Administration"},{"key":"10.1016\/j.jsat.2021.108590_bb0095","author":"Substance Abuse and Mental Health Services Administration"},{"issue":"1","key":"10.1016\/j.jsat.2021.108590_bb0105","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1940-0640-9-3","article-title":"Outcomes among buprenorphine-naloxone primary care patients after hurricane Sandy","volume":"9","author":"Tofighi","year":"2014","journal-title":"Addiction Science & Clinical Practice"},{"key":"10.1016\/j.jsat.2021.108590_bb0110","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41380-020-00880-7","article-title":"COVID-19 risk and outcomes in patients with substance use disorders: Analyses from electronic health records in the United States","volume":"26","author":"Wang","year":"2021","journal-title":"Molecular Psychiatry"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547221003160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547221003160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:56:41Z","timestamp":1760039801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547221003160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":20,"alternative-id":["S0740547221003160"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2021.108590","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Did drug use increase following COVID-19 relaxation of methadone take-out regulations? 2020 was a complicated year","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2021.108590","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108590"}}